Evidence That Circulating T Cells at Treatment Onset Predict Response to PD-1 Inhibitors

Annals of Case Reports, Год журнала: 2024, Номер 9(3)

Опубликована: Май 6, 2024

The present study aims to identify the potential role of circulating lymphocytic subpopulations as biomarkers for response anti-PD-1 immunotherapy. Twenty-one cancer patients who were about start treatment with either nivolumab or pembrolizumab and eight healthy donors enrolled. Peripheral blood mononuclear cells obtained flow cytometric analysis at five consecutive time points up six months. Total CD4+lymphocytes significantly decreased, whereas T helper 17 regulatory lymphocytes increased within non-responders compared onset, indicating their significance predicting non-response CPI However, further validation is required.

Язык: Английский

---

Progress in Diagnosis, Treatment and Prediction of Rheumatic Adverse Events Associated with Immune Checkpoint Inhibitors

Advances in Clinical Medicine, Год журнала: 2024, Номер 14(09), С. 503 - 510

Опубликована: Янв. 1, 2024

Язык: Английский

---

Activation of T cell checkpoint pathways during β‐cell antigen presentation by engineered dendritic cells promotes protection from type 1 diabetes

Immunology, Год журнала: 2022, Номер 166(3), С. 341 - 356

Опубликована: Апрель 11, 2022

Abstract Defective immune regulation has been recognized in type 1 diabetes (T1D). Immune regulatory T cell check‐point receptors, which are generally upregulated on activated cells, have the molecules of attention as therapeutic targets for enhancing response tumour therapy. Here, we show that pancreatic β‐cell antigen (BcAg) presentation by engineered tolerogenic dendritic cells (tDCs) express CTLA4 selective ligand (B7.1wa) or a combination CTLA4, PD1 and BTLA ligands (B7.1wa, PD‐L1 HVEM‐CRD1 respectively; multiligand‐DCs) causes an increase cytokine (Treg) responses suppression effector function compared with control‐DCs. Non‐obese diabetic mice treated BcAg‐pulsed CTLA4‐ligand‐DCs multiligand‐DCs at pre‐diabetic early‐hyperglycaemic stages showed significantly lower degree insulitis, higher frequencies insulin‐positive islets, profound delay reversal hyperglycaemia significant duration. from tDC‐treated not only produced amounts IFNγ IL10 TGFβ1 upon BcAg challenge, but also failed to induce adoptive transfer. While both were effective inducing tolerance, multiligand‐DC treatment overall suppressive effect disease outcome. These studies enhanced engagement checkpoint receptors during can modulate suppress autoimmunity progression T1D.

Язык: Английский

---

Association of Blood Biomarkers and Autoimmunity with Immune Related Adverse Events in Patients with Cancer treated with Immune Checkpoint Inhibitors

Research Square (Research Square), Год журнала: 2021, Номер unknown

Опубликована: Янв. 4, 2021

Abstract Background: Patients with cancer treated immune checkpoint inhibitors (ICIs) develop related adverse events (irAEs), however biomarkers are lacking. We hypothesized that clinicopathologic and laboratory factors would be associated irAE risk overall survival (OS) in this population. Methods: In a retrospective study of patients ICIs we collected clinicopathologic, laboratory, irAEs outcomes data. The association between baseline blood biomarkers, features was assessed by logistic regression adjusting for age, sex, smoking, type, performance status, concomitant other systemic therapy, history autoimmune disease (AD) chronic infection. Optimal cutoff values were identified recursive partitioning analysis. Results: 470 identified; 156 (33%) developed irAEs, which absolute lymphocyte count >2.6k/ul (adjusted [a]OR:4.12), neutrophil to ratio (NLR) ≤5.3 (aOR:2.08) monocyte (MLR)≤0.73 (aOR:3.11). pre-existing AD (aOR:2.81), family (aOR:5.86), ICI combination (aOR:2.26) had higher odds irAEs. Baseline NLR≤5.3 (aHR:0.68) MLR≤0.73 (aHR:0.43) longer OS. Conclusion: history, measurements. Lower NLR MLR may have favorable prognostic value. Our hypothesis-generating findings require validation larger prospective studies.

Язык: Английский

---

Rheumatological Adverse Events Following Immunotherapy for Cancer

Medicina, Год журнала: 2022, Номер 58(1), С. 94 - 94

Опубликована: Янв. 8, 2022

Background and Objectives: The occurrence of rheumatological side effects in a patient after receiving immunotherapy for cancer is becoming increasingly common. Oncologists often fail to diagnose refer affected patients rheumatologists. This paper presents the various adverse events that occur as well their treatment evolution. Materials Methods: A total 36 were monitored between November 2018 March 2020. oncologist monitoring immunotherapy-treated identified musculoskeletal effects. grading toxicities was performed by both rheumatologist using common terminology criteria (CTCAE). Rheumatological administered, some patients, discontinued. Results: clinical presentations varied. Mild (grade 1-2) reported higher proportion than severe 3-5). Therefore, thirty-one had mild-to-moderate effects, five Adverse reactions occurred, on average, 10 weeks initiation immunotherapy; this indicated severity toxicity dose dependent. Patients treated with NSAIDs or prednisone, depending manifestations, remission rheumatic manifestations varied grade manifestations. Conclusions: clinical, biological, ultrasound followed treatments differed from classic Thorough examinations these oncologists rheumatologists are needed order correctly treat events. Multiple studies include larger number participants better understand pathogenesis evolution under different conditions.

Язык: Английский

---